# Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

> **NCT03507465** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 290 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole Plus Low-Dose Metronomic Capecitabine
- **DRUG:** EC-T

## Key facts

- **NCT ID:** NCT03507465
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-29
- **Primary completion:** 2019-11-29
- **Final completion:** 2020-11-29
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507465, "Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03507465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*